KIT and Autoimmunity: This NMA regimen includes (a) antibody targeting of CD117 (c-Kit), a receptor tyrosine kinase essential for HSC proliferation and survival through the binding of stem cell factor (21), and (b) inhibition of JAK/STAT signaling to overcome substantial NK cell and T cell barriers to allogeneic transplant in the setting of autoimmunity (22–24).